Andrew Cittadine

This profile gathers the share dealings of Andrew Cittadine in Monopar Therapeutics, where the filings describe the role as senior executive. We count 46 filings; the first trade dates from 30 June 2022 and the latest from 30 September 2026.

Every open-market trade on record is a purchase: 12 purchases worth €141k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 17 share grants and 17 option exercises.

The median purchase comes to €9,831. No cluster: in 12 purchases, no other insider of the company bought within 30 days.

Most recently, on 2 October 2026, the filings show an option exercise in Monopar Therapeutics. The latest purchase dates back some time: it was published 870 days ago, on 21 June 2024. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.